Nonenzymatic conversion of 3,4-dihydroxyphenylalanine to 2,4,5-trihydroxyphenylalanine and 2,4,5-trihydroxyphenylalanine quinone in physiological solutions.
2,4,5-Trihydroxyphenylalanine (TOPA) oxidizes in solution to form a quinone derivative that is a non-N-methyl-D-aspartate agonist and neurotoxin. Although pathways have been postulated for the formation of both TOPA and TOPA quinone from closely related catecholamines, the generation of these compounds has not been conclusively demonstrated by analytical techniques. Reverse-phase HPLC with a dual electrode coulometric detector was used to analyze TOPA containing solutions in an effort to rigorously characterize the behavior of this substance under physiological conditions. Electrode potential, buffer system, and methanol concentration were varied to obtain optimal conditions to selectively detect and quantify TOPA and TOPA quinone from closely related catecholamines. TOPA was shown to rapidly autoxidize to TOPA quinone by a process dependent on pH. TOPA was the dominant species at acidic pHs (below 5-6), whereas TOPA quinone was dominant at physiological pHs. This conversion was reversible upon acidification. In addition, we found that 3,4-dihydroxyphenylalanine can autoxidize to form both TOPA and TOPA quinone under physiological conditions. This partial conversion (0.5%) is time dependent and can be substantially decreased (0.2%) in acidic conditions (pH < or = 3). These results suggest that some of the excitatory and excitotoxic properties that some investigators have attributed to DOPA may actually be due to its conversion to TOPA and TOPA quinone.
Newcomer
T A
TA
Department of Physiology, University of Pittsburgh School of Medicine, Pennsylvania 15261.
Palmer
A M
AM
Rosenberg
P A
PA
Aizenman
E
E
D002021:Buffers; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives* / Q000032:analysis / Q000378:metabolism*; D006863:Hydrogen-Ion Concentration; D009638:Norepinephrine / Q000032:analysis; D010084:Oxidation-Reduction; D012996:Solutions
D002021:Buffers; D012996:Solutions; C001388:6-hydroxydopa; D004295:Dihydroxyphenylalanine; C067626:6-hydroxydopa quinone; D009638:Norepinephrine